Nicole A Doudican et al., 2013-02: Doudican et al. report that oral mebendazole matches temozolomide against melanoma xenografts and acts through BCL2 phosphorylation and XIAP downregulation.
We now show that in a human xenograft melanoma model, oral MBZ is as effective as the current standard of care temozolomide in reducing tumor growth.
Nicole A Doudican et al., 2013-02: Doudican et al. report that oral mebendazole matches temozolomide against melanoma xenografts and acts through BCL2 phosphorylation and XIAP downregulation. Study type: human melanoma xenograft in mice. N: not stated in the abstract. Country: USA (NYU School of Medicine). Dose: not stated in the abstract text captured; route oral. The ReDO review records this study's dosing as 1 mg or 2 mg orally every other day. Funder: not stated in the record. Declared conflicts: no COI statement in the record. Comparator: temozolomide 100 mg/kg intraperitoneally for 5 days as the positive control, and untreated mice. Study type: animal.
